Market

Stellantis recalls heavy duty diesel Rams to fix fuel pumps



The Stellantis sign outside is shown on Jan. 19, 2021 at the Chrysler Technology Center in Auburn Hills, Mich. Stellantis is recalling more than 240,000 diesel heavy-duty trucks, Wednesday, Nov. 17, mainly in North America to fix fuel pumps that can fail and cause engine stalling. (AP Photo/Carlos Osorio, File)

DETROIT (AP) — Stellantis is recalling more than 240,000 diesel heavy-duty trucks, mainly in North America, to fix fuel pumps that can fail and cause engine stalls.

The recall covers certain 2019 and 2020 heavy-duty pickups and chassis cab trucks equipped with 6.7-liter Cummins diesel engines.

The recall comes about a month after the National Highway Traffic Safety Administration opened an investigation into the pump failures. But Stellantis says the company started its recall determination process before the probe was announced.

The safety agency said that in November of 2019, Fiat Chrysler (now Stellantis), maker of the trucks, issued a warranty bulletin to dealers telling them to collect fuel pumps on the trucks.

Stellantis says some of the pumps can wear and contaminate their mechanisms with metal shavings, causing engines to stall or fail to start.

Dealers will replace the pumps at no cost to owners, who will be notified by letters starting next month.

Federal safety investigators opened the probe after getting 22 complaints and two field reports of engines stalling. There were no reports of crashes or injuries.

7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that
are ready to make strong moves forward in 2022.

View the “7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022”.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

close